Disclaimer: The Views/Opinions expressed and/or opinions provided in Videos and other content on MedEnrich Website are those of respective speakers. They do not purport to reflect the opinion or views of Dr.Reddy’s Laboratories Limited or its affiliates (collectively Dr.Reddy’s)in any manner whatsoever and accordingly ,Dr.Reddys does not recommend , endorse or make any representation about the veracity and appropriateness of the views ,opinions/ information on MedEnrich website. Content on MedEnrich website may discuss uses and dosage for therapeutic product that may not have been approved in by the relevant regulatory agencies in your country. Dr.Reddy’s does not support , endorse or encourage any off-label use. Please refer to approved label before prescribing.
Duration of trastuzumab in patients with Her2 positive Metastatic Breast Cancer in prolonged remission
Breast Cancer Published 1 year ago
Improving outcomes in patients with Brain Metastases of Breast Cancer
Breast Cancer Published 1 year ago
Content
Breast Cancer
11m 43s
Sequencing of treatment for Her2 positive MBC in 2022
Published 07 Jul 2022
Noteworthy treatment options added in the treatment guidelines for Her2 positive MBC are Trastuzumab Deruxtecan (TDXd) and combination of Trastuzumab + Capecitabine +Tucatinib. In landmark Destiny Breast 03 study TDXd showed significant PFS benefit compared to TDM1 in Her2 positive MBC patients who have received prior Trastuzumab and Taxane. HER2CLIMB study showed significant PFS & OS benefit for combination of Trastuzumab + Capecitabine +Tucatinib and retained significant activity in patients with brain metastases not requiring immediate treatment.
